Analytical Data
-
Gene name
SSX5
- Application
-
Alternative Names
SSX5；Protein SSX5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60225
-
Expression Region
1-229aa
-
AA Sequence
MNGDDAFVRRPRVGSQIPQKMQKHPWRQVCDRGIHLVNLSPFWKVGREPASSIKALLCGRGEARAFDDIAKYFSEKEWEKMKASEKIIYVYMKRKYEAMTKLGFKATLPPFMRNKRVADFQGNDFDNDPNRGNQVEHPQMTFGRLQGIFPKITPEKPAEEGNDSKGVPEASGPQNNGKQLRPSGKLNTSEKVNKTSGPKRGKHAWTHRVRERKQLVIYEEISDPQEDDE
-
Molecular Weight
53.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX5 is a member of the SSX gene family, known for its role in cancer immunology as a cancer/testis (CT) antigen. These antigens are typically expressed in the testis but not in normal somatic tissues, making them promising targets for cancer immunotherapy. SSX5 specifically has garnered interest due to its expression in various malignancies, including melanoma and other solid tumors, suggesting a potential role in tumor progression and immune evasion. Research on SSX5 recombinant proteins aims to understand their structure, function, and interaction with the immune system. By producing SSX5 proteins through recombinant DNA technology, scientists seek to evaluate their immunogenicity and potential as therapeutic targets. Studies have shown that SSX5 can elicit T-cell responses, making it a candidate for vaccine development. Additionally, investigating SSX5's expression patterns and mutation status in tumors can shed light on its role in oncogenesis. Overall, the study of SSX5 recombinant proteins stands at the intersection of molecular biology and clinical oncology, promising advancements in targeted immunotherapies for cancer treatment.
